Skip to Content

Rapraeger Lab

From Human Oncology

Jump to: navigation, search
Adhesion signaling diagram
The Rapraeger group seeks to develop new therapeutics that target receptor tyrosine kinases linked to cell adhesion signaling mechanisms in cancer. Our focus is on the syndecans (Sdc) family of cell-matrix receptors; the syndecans act as organizers of receptor complexes containing integrins and receptor tyrosine kinases (EGFR, IGF1R, VEGFR2 and others) that drive tumorigenesis and angiogenesis. We are developing synstatins (SSTNs) – therapeutic peptides that disrupt these signaling mechanisms and block tumor growth, survival and invasion, as well as tumor-induced angiogenesis.